IRVINE, Calif., May 9, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, announced today its 2nd annual workshop, titled, 'Process Considerations for Cryogenic and Regenerative Medicine Commercialization,' taking place on Wednesday, May 15, 2019 at the Business Design Centre in London, United Kingdom. The educational workshop is taking place in conjunction with the World Advanced Therapies & Regenerative Medicine Congress event and is aimed at biotechnology and pharmaceutical professionals who want to learn more about the critical considerations for the development and commercialization of vital regenerative medicine therapies.
The workshop will feature topics on:
- Integration and Data Continuity Throughout the Regenerative Medicine Production Process
- Systems Compliance and Traceability During Product Distribution
- Regenerative Medicine Globalization: Considerations for Effective Launch activity Beyond your Initial Geographic Launch
- Scalability (Systems, Data, Infrastructure)
The workshop will include speakers from groundbreaking companies in the regenerative medicine market, including Cryoport, GE Healthcare, Be The Match BioTherapies, Mesoblast, Eversana, Hitachi Chemical Advanced Therapeutic Solutions, Progenitor Therapeutics and Royal Free London NHS Foundation Trust.
Mark Sawicki, Chief Commercial Officer at Cryoport, commented, "The emergence of regenerative medicine is shaping up to be one of the greatest achievements of modern medicine. However, regenerative medicine commodities are inherently fragile and more at risk than other products during the supply chain process. Cross-contamination, orientation and handling problems, and equipment failure all have the potential to damage these irreplaceable materials. This workshop brings together dedicated individuals and companies that are at the forefront of the regenerative medicine industry and who are committed to overcoming these challenges in order to bring life changing therapies to patients. With new regulations anticipated to affect all aspects of the collection, manufacture, transportation, and administration of regenerative medicines, it is now more important than ever for biopharmaceutical companies to be aware of best practices when advancing their therapies through the clinical trial pipeline and into commercialization. This workshop will prove to be a great platform for learning and collaboration for those involved in regenerative medicine."
About the World Advanced Therapies & Regenerative Medicine Congress
The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today. The 2019 edition will be in its 14th year and it continues to grow and attract a large audience of biotech, pharma, start-ups, investors, research and technology companies from around the world. The conference and exhibition will host over 1,000 attendees, 300 speakers and 80 exhibition booths. Over 500 different global companies are represented every year at this event.
About Cryoport, Inc.
Cryoport is the life sciences industry's most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR T-cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal® Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to: simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting; delivering the most advanced temperature-controlled logistics solutions for the life sciences industry; and providing vital information that provides peace of mind throughout the life of each logistics process.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the Company's 10-K for the year ended December 31, 2018 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
SOURCE Cryoport, Inc.